Factor VIII

• 

  Subject Areas on Research

  • A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A. 
  • ABO blood group influences transfusion and survival after cardiac surgery. 
  • Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. 
  • Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. 
  • Bovine retinal explants cultured in collagen gels. A model system for the study of proliferative retinopathy. 
  • Carbohydrate on human factor VIII/von Willebrand factor. Impairment of function by removal of specific galactose residues. 
  • Cellular interactions in hemostasis. 
  • Circulating anticoagulants to factor VIII. Immunochemical studies and clinical response to factor VIII concentrates. 
  • Cloned endothelium derived from autoimmune vascular disease retain structural and functional characteristics of normal endothelial cells. 
  • Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. 
  • Contemporary issues in the management of von Willebrand disease. 
  • Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding. 
  • Cryoprecipitate therapy. 
  • Cryoprecipitate transfusion in bleeding patients. 
  • Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets. 
  • Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII. 
  • Electron microscopy of human factor VIII/Von Willebrand glycoprotein: effect of reducing reagents on structure and function. 
  • Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux. 
  • Endothelial cell surface expression and binding of factor VIII/von Willebrand factor. 
  • Evaluation of a modified procedure for Staclot LA for the confirmation of lupus anticoagulants. 
  • Evidence for cellular heterogeneity in primary cultures of human orbital fibroblasts. 
  • Excess factor VIII and hypercoagulability. 
  • Experimental transfusion reactions and disseminated intravascular coagulation produced by incompatible plasma in monkeys. 
  • Factor VIII Arg2304 --> His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex. 
  • Factor VIII/von Willebrand protein. Modification of its carbohydrate causes reduced binding to platelets. 
  • Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. 
  • Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. 
  • Fibrinogen content of low-volume cryoprecipitate. 
  • Gene therapies for hemophilia hit the mark in clinical trials. 
  • Global sources of cryoprecipitate demonstrate variability in coagulant factor levels and functional hemostasis. 
  • HTLV-III seroconversion associated with heat-treated factor VIII concentrate. 
  • Haemostasis: from bench to bedside. 
  • Hepatitis C infection in children with hemophilia A and B. 
  • Human splenic sinusoidal lining cells express antigens associated with monocytes, macrophages, endothelial cells, and T lymphocytes. 
  • Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Immunohistochemical studies of cell differentiation in a juxtaglomerular tumor. 
  • Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. 
  • Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes. 
  • Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. 
  • Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. 
  • Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity. 
  • Intracerebral hematoma in a hemophiliac. Combined surgical and factor VIII treatment. 
  • Intraretinal neovascularization in diabetic retinopathy. 
  • Is there a precursive, relatively procoagulant-inactive form of normal antihemophilic factor (factor VIII)? 
  • Isolated vocal cord hematoma in a child with severe factor VIII deficiency. 
  • Isolation and purification of canine adipose microvascular endothelial cells. 
  • Lack of thromboxane A2 synthesis in platelet aggregation induced by factor VIII/von Willebrand factor. 
  • Localization of factor VIII/von Willebrand factor and glial fibrillary acidic protein in the hemangioblastoma: implications for stromal cell histogenesis. 
  • Lymph node infarction: role of underlying malignancy, tumour proliferation fraction and vascular compromise--a study of 35 cases and a comprehensive review of the literature. 
  • Management of a patient with type IIC von Willebrand's disease during coronary artery bypass graft surgery. 
  • Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. 
  • Modulation of platelet shape and membrane receptor binding by Ca2+-calmodulin complex. 
  • Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. 
  • Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIII. 
  • Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. 
  • Platelet procoagulant complex assembly in a tissue factor-initiated system. 
  • Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation. 
  • Procoagulant and platelet aggregating properties of antilymphocyte sera. 
  • Reduction in blood transfusion in a cohort of infants having cardiac surgery with cardiopulmonary bypass after instituting a goal-directed transfusion policy. 
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. 
  • Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. 
  • Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. 
  • Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation. 
  • Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. 
  • Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. 
  • Spontaneously acquired anti-factor VIII antibodies: report of a patient with adenocarcinoma of the prostate. 
  • Successful prophylactic regimens for transvaginal oocyte retrieval in women with bleeding diatheses. 
  • Sustained expression of human factor VIII in mice using a parvovirus-based vector. 
  • The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor VIII concentrations. 
  • The basis for the increase in factor VIII procoagulant activity during exercise. 
  • The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation. 
  • The characterization of twenty sequenced human genomes. 
  • The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. 
  • The subunit structure of normal and hemophilic factor VIII. 
  • Thrombin activates factor XI on activated platelets in the absence of factor XII. 
  • Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa. 
  • Total knee arthroplasty in hemophilia. 
  • Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. 
  • Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor. 
  • Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. 
  • von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). 
  • von Willebrand disease in the 21st century: current approaches and new challenges. 
• 

  Keywords of People

  • Erickson, Harold Paul, James B. Duke Distinguished Professor of Cell Biology, Cell Biology
  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Lagoo, Anand Shreeram, Professor of Pathology, Pathology
  • Levy, Jerrold Henry, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology